Adrián Sánchez-Montalvá

12PUBLICATIONS
42CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMajor global burdens of diseaseEpidemiological methodsComputational physiology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Dec 08, 2025
Multicentre controlled open randomised clinical trial to assess efficacy and safety of an anti-tuberculosis drug combination based on optimised-dose rifampicin, optimised-dose moxifloxacin and optimised-dose linezolid for TB: the RML-TB trial protocol.

Laura Diab Casares, Juan Espinosa Pereiro, María Teresa Tórtola Fernández

|Jul 28, 2025
A machine learning model exploring the relationship between chronic medication and COVID-19 clinical outcomes.

Berta Miró, Natalia Díaz González, Juan-Francisco Martínez-Cerdá

|May 28, 2025
Molecular Epidemiology of Travel-Associated and Locally Acquired Dengue Virus Infections in Catalonia, Spain, 2019.

Jéssica Navero-Castillejos, Adrián Sánchez-Montalvá, Elena Sulleiro

|Jan 10, 2025
Safety, Efficacy, and Pharmacokinetics of Daily Optimized Doses of Rifampicin for the Treatment of Tuberculosis: A Systematic Review and Bayesian Network Meta-Analysis.

Juan Espinosa-Pereiro, Ana Aguiar, Eva Nara

|Aug 21, 2024
Usefulness of Xpert MTB/RIF and Xpert Ultra to Categorize Risk of Tuberculosis Transmission to Household Contacts.

Alexander Mol, Adrián Sánchez-Montalvá, Juan Espinosa-Pereiro

|Nov 13, 2023
A Systematic Review of Potential Biomarkers for Bacterial Burden and Treatment Efficacy Assessment in Tuberculosis Platform-Based Clinical Trials.

Juan Espinosa-Pereiro, Riccardo Alagna, Francesca Saluzzo

Pageof 2

Frequent Collaborators

4 joint publications

Juan Espinosa-Pereiro

3 joint publications

Pau Bosch-Nicolau

3 joint publications

Maria Luisa Aznar

2 joint publications

Elena Sulleiro